Overview

A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
There is an unsatisfied medical need for a first-line treatment of lymphatic malformations with a good benefit/risk profile. Based on a patient experience in the institution, the investigators plan to verify whether or not the medication sildenafil has a beneficial effect on lymphatic malformations. The investigators plan to do this by treating patients with lymphatic malformations with the medication sildenafil for a 20 week period. This is an investigator initiated study funded by an Innovations in Patient Care grant and a SPARK grant.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Stanford University
Treatments:
Sildenafil Citrate